Naproxcinod Approval Status
- FDA approved: No
- Generic name: naproxcinod
- Company: NicOx S.A.
- Treatment for: Duchenne Muscular Dystrophy
Naproxcinod is the first in a new class of anti-inflammatory agents known as CINODs (Cyclooxygenase-Inhibiting Nitric Oxide Donators) in development for the treatment of Duchenne Muscular Dystrophy.
Development Status and FDA Approval Process for naproxcinod
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.